Cristiana M Toscano

List of Publications by Year
in descending order

56 papers	1,287 citations	331670 21 h-index	395702 33 g-index
62 all docs	62 docs citations	62 times ranked	2144 citing authors

#	Article	IF	Citations
1	Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review. PLoS ONE, 2016, 11, e0166736.	2.5	102
2	A Model for Enhancing Evidence-Based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: Paho's Provac Initiative. Public Health Reports, 2007, 122, 811-816.	2.5	70
3	Cost of management of severe pneumonia in young children: systematic analysis. Journal of Global Health, 2016, 6, 010408.	2.7	65
4	Medidas de distanciamento social para o enfrentamento da COVID-19 no Brasil: caracterizaÃ§Ã£o e anÃ¡lise epidemiolÃ³gica por estado. Cadernos De Saude Publica, 2020, 36, e00185020.	1.0	62
5	Infection due to extended-spectrum Î²-lactamase-producing Salmonella enterica subsp. enterica serotype infantis in a neonatal unit. Journal of Pediatrics, 2002, 141, 381-387.	1.8	53
6	Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative. Vaccine, 2011, 29, 1099-1106.	3.8	51
7	Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study. International Journal of Environmental Research and Public Health, 2018, 15, 89.	2.6	50
8	Impact of Kasai portoenterostomy on liver transplantation outcomes: A retrospective cohort study of 347 children with biliary atresia. Liver Transplantation, 2015, 21, 922-927.	2.4	43
9	Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses. Vaccine, 2016, 34, 4738-4743.	3.8	42
10	Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis. PLoS ONE, 2017, 12, e0184204.	2.5	39
11	Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean. American Journal of Tropical Medicine and Hygiene, 2020, 103, 593-596.	1.4	36
12	Bacterial Meningitis in Brazil: Baseline Epidemiologic Assessment of the Decade Prior to the Introduction of Pneumococcal and Meningococcal Vaccines. PLoS ONE, 2013, 8, e64524.	2.5	35
13	Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data. PLoS ONE, 2016, 11, e0153141.	2.5	33
14	Sepsis-related deaths in Brazil: an analysis of the national mortality registry from 2002 to 2010. Critical Care, 2014, 18, 608.	5.8	31
15	Disease and Economic Burden of Hospitalizations Attributable to Diabetes Mellitus and Its Complications: A Nationwide Study in Brazil. International Journal of Environmental Research and Public Health, 2018, 15, 294.	2.6	31
16	Cost effectiveness of OptiMalÂ® rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil. Malaria Journal, 2010, 9, 277.	2.3	27
17	Etiologies of Rash and Fever Illnesses in Campinas, Brazil. Journal of Infectious Diseases, 2011, 204, S627-S636.	4.0	26
18	Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: A follow up study. BMC Health Services Research, 2008, 8, 189.	2.2	25

#	Article	IF	Citations
19	Systematic documentation of new vaccine introduction in selected countries of the Latin American Region. Vaccine, 2013, 31, C114-C122.	3.8	24
20	ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine, 2015, 33, A21-A27.	3.8	24
21	Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries. Clinical Infectious Diseases, 2021, 73, 306-313.	5.8	24
22	Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Review of Vaccines, 2016, 15, 1295-1304.	4.4	22
23	Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS ONE, 2017, 12, e0179222.	2.5	22
24	Measles transmission during commercial air travel in Brazil. Journal of Clinical Virology, 2006, 36, 235-236.	3.1	21
25	Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: The roles of needleless device use, bathing practices, and catheter care. American Journal of Infection Control, 2009, 37, 327-334.	2.3	20
26	Pneumococcal disease manifestation in children before and after vaccination: What's new?. Vaccine, 2011, 29, C2-C14.	3.8	20
27	Using standardized tools to improve immunization costing data for program planning: The cost of the Colombian Expanded Program on Immunization. Vaccine, 2013, 31, C72-C79.	3.8	20
28	A nationwide population screening program for diabetes in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2004, 16, 320-7.	1.1	20
29	Multi-institutional outbreak of Burkholderia cepacia complex associated with contaminated mannitol solution prepared in compounding pharmacy. American Journal of Infection Control, 2013, 41, 1038-1042.	2.3	19
30	Reprocessing and Reuse of Single-Use Medical Devices Used During Hemodynamic Procedures in Brazil: A Widespread and Largely Overlooked Problem. Infection Control and Hospital Epidemiology, 2008, 29, 854-858.	1.8	18
31	Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. Diabetology and Metabolic Syndrome, 2015, 7, 95.	2.7	16
32	Cost-effectiveness of Sick Leave Policies for Health Care Workers with Influenza-like Illness, Brazil, 2009. Emerging Infectious Diseases, 2011, 17, 1421-9.	4.3	15
33	Establishing a regional network of academic centers to support decision making for new vaccine introduction in Latin America and the Caribbean: The ProVac experience. Vaccine, 2013, 31, C12-C18.	3.8	14
34	Ocular myositis and diffuse meningoencephalitis from Trypanosoma cruzi in an AIDS patient. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 535-536.	1.8	13
35	Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome. Journal of Infectious Diseases, 2015, 212, 57-66.	4.0	13
36	Performing Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean. Value in Health Regional Issues, 2012, 1, 248-253.	1.2	12

#	Article	IF	Citations
37	Cost analysis of an integrated vaccine-preventable disease surveillance system in Costa Rica. Vaccine, 2013, 31, C88-C93.	3.8	12
38	Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean. Vaccine, 2013, 31, C33-C44.	3.8	10
39	Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean. Vaccine, 2013, 31, C45-C57.	3.8	10
40	Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses. Vaccine, 2020, 38, 7033-7039.	3.8	10
41	Sexually transmitted diseases in Latin America and the Caribbean. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 1999, 6, 362-370.	1.1	8
42	Historical Analysis of Birth Cohorts Not Vaccinated Against Rubella Prior to National Rubella Vaccination Campaign, Brazil. Journal of Infectious Diseases, 2011, 204, S608-S615.	4.0	7
43	Improved calibration estimators for the total cost of health programs and application to immunization in Brazil. PLoS ONE, 2019, 14, e0212401.	2.5	6
44	Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries. Vaccine, 2021, 39, 147-157.	3.8	6
45	Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings: A dynamic transmission model of pertussis in three Brazilian states. Vaccine, 2021, 39, 125-136.	3.8	6
46	Rubella virus genotype 1G and echovirus 9 as etiologic agents of exanthematous diseases in Brazil: insights from phylogenetic analysis. Archives of Virology, 2013, 159, 1445-51.	2.1	5
47	Effectiveness of Pneumococcal Vaccines on Otitis Media in Children: A Systematic Review. Value in Health, 2022, 25, 1042-1056.	0.3	5
48	Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil. Vaccine, 2021, 39, 158-166.	3.8	4
49	Impact of pneumococcal conjugate vaccine uptake on childhood pneumonia mortality across income levels in Brazil, Colombia, and Peru. Gates Open Research, 2020, 4, 136.	1.1	4
50	Effects of non-pharmaceutical interventions on social distancing during the COVID-19 pandemic: Evidence from the 27 Brazilian states. PLoS ONE, 2022, 17, e0265346.	2.5	4
51	Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean. Lancet Infectious Diseases, The, 2021, 21, 306-308.	9.1	3
52	The data used to build the models: Pertussis morbidity and mortality burden considering various Brazilian data sources. Vaccine, 2021, 39, 137-146.	3.8	3
53	Evaluating the cost-effectiveness of maternal pertussis immunization in low- and middle-income countries: A review of lessons learnt. Vaccine, 2021, 39, 121-124.	3.8	3
54	Bacterial etiology of pneumonia in children up to 2 months of age: a systematic review. Gates Open Research, 0, 6, 15.	1.1	1

#	Article	IF	Citations
55	Response to comment on: Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses. Vaccine, 2017, 35, 4826-4827.	3.8	0
56	Assessment of the implementation of a nurse-initiated pain management protocol in the emergency department. Revista Brasileira De Enfermagem, 2021, 74, e20201303.	0.7	0